These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 27149299)

  • 1. Have artificial neural networks met expectations in drug discovery as implemented in QSAR framework?
    Dobchev D; Karelson M
    Expert Opin Drug Discov; 2016 Jul; 11(7):627-39. PubMed ID: 27149299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The advancement of multidimensional QSAR for novel drug discovery - where are we headed?
    Wang T; Yuan XS; Wu MB; Lin JP; Yang LR
    Expert Opin Drug Discov; 2017 Aug; 12(8):769-784. PubMed ID: 28562095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A renaissance of neural networks in drug discovery.
    Baskin II; Winkler D; Tetko IV
    Expert Opin Drug Discov; 2016 Aug; 11(8):785-95. PubMed ID: 27295548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neural networks in building QSAR models.
    Baskin II; Palyulin VA; Zefirov NS
    Methods Mol Biol; 2008; 458():137-58. PubMed ID: 19065809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative structure-activity relationship: promising advances in drug discovery platforms.
    Wang T; Wu MB; Lin JP; Yang LR
    Expert Opin Drug Discov; 2015 Dec; 10(12):1283-300. PubMed ID: 26358617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of neural networks for drug discovery and the inputs used.
    Xu Y; Yao H; Lin K
    Expert Opin Drug Discov; 2018 Dec; 13(12):1091-1102. PubMed ID: 30449189
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular topology as a novel approach for drug discovery.
    Gálvez J; Gálvez-Llompart M; García-Domenech R
    Expert Opin Drug Discov; 2012 Feb; 7(2):133-53. PubMed ID: 22468915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial Neural Networks in Computer-Aided Drug Design: An Overview of Recent Advances.
    Cheirdaris DG
    Adv Exp Med Biol; 2020; 1194():115-125. PubMed ID: 32468528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Science of the science, drug discovery and artificial neural networks.
    Patel J
    Curr Drug Discov Technol; 2013 Mar; 10(1):2-7. PubMed ID: 22725688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural network and deep-learning algorithms used in QSAR studies: merits and drawbacks.
    Ghasemi F; Mehridehnavi A; Pérez-Garrido A; Pérez-Sánchez H
    Drug Discov Today; 2018 Oct; 23(10):1784-1790. PubMed ID: 29936244
    [No Abstract]   [Full Text] [Related]  

  • 11. Multitasking models for quantitative structure-biological effect relationships: current status and future perspectives to speed up drug discovery.
    Speck-Planche A; Cordeiro MN
    Expert Opin Drug Discov; 2015 Mar; 10(3):245-56. PubMed ID: 25613725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4D- quantitative structure-activity relationship modeling: making a comeback.
    Fourches D; Ash J
    Expert Opin Drug Discov; 2019 Dec; 14(12):1227-1235. PubMed ID: 31513441
    [No Abstract]   [Full Text] [Related]  

  • 13. Improving quantitative structure-activity relationship models using Artificial Neural Networks trained with dropout.
    Mendenhall J; Meiler J
    J Comput Aided Mol Des; 2016 Feb; 30(2):177-89. PubMed ID: 26830599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What are artificial neural networks and what they can do?
    Dohnal V; Kuca K; Jun D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):221-4. PubMed ID: 16601760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latest advances in molecular topology applications for drug discovery.
    Zanni R; Galvez-Llompart M; García-Domenech R; Galvez J
    Expert Opin Drug Discov; 2015; 10(9):945-57. PubMed ID: 26134383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QSAR studies in the discovery of novel type-II diabetic therapies.
    Abuhammad A; Taha MO
    Expert Opin Drug Discov; 2016; 11(2):197-214. PubMed ID: 26558613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative structure-toxicity relationships by accelerated cytotoxicity mechanism screening.
    Siraki AG; Chevaldina T; Moridani MY; O'Brien PJ
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):118-25. PubMed ID: 14982155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neural network studies. 2. Variable selection.
    Tetko IV; Villa AE; Livingstone DJ
    J Chem Inf Comput Sci; 1996; 36(4):794-803. PubMed ID: 8768768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of artificial neural networks in the QSAR prediction of physicochemical properties and toxicities for REACH legislation.
    Dearden JC; Rowe PH
    Methods Mol Biol; 2015; 1260():65-88. PubMed ID: 25502376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of artificial neural networks in medical science.
    Patel JL; Goyal RK
    Curr Clin Pharmacol; 2007 Sep; 2(3):217-26. PubMed ID: 18690868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.